Literature DB >> 30977909

miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 in vitro and in vivo.

Cheng-Long Chen1, Long Zhang2, Yu-Rui Jiao1, Yi Zhou3, Qiao-Feng Ge1, Peng-Cui Li4, Xiao-Juan Sun4, Zhi Lv2.   

Abstract

miR-134 has been shown to be associated with angiogenesis and the progression of osteosarcoma. This study further assessed the effects of miR-134 expression on osteosarcoma cell migration, invasion, and metastasis in vitro and in a nude mouse xenograft model, exploring the underlying molecular events. Luciferase reporter assays revealed that miR-134 directly targets the 3'-UTRs of MMP1 and MMP3 to reduce their expression in osteosarcoma cells. In conclusion, overexpression of miR-134 suppresses osteosarcoma cell invasion and metastasis through the inhibition of MMP1 and MMP3 expression. We propose miR-134 as an attractive novel therapeutic target for the treatment of osteosarcoma.
© 2019 Federation of European Biochemical Societies.

Entities:  

Keywords:  invasion; matrix metalloproteinases; metastasis; miR-134; osteosarcoma

Mesh:

Substances:

Year:  2019        PMID: 30977909     DOI: 10.1002/1873-3468.13387

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Overexpression of BRINP3 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration via MAP4 in Osteosarcoma.

Authors:  Wenchao Zeng; Huiya Xu; Tian Wei; Huishan Liang; Xiaokun Ma; Fen Wang
Journal:  Dis Markers       Date:  2022-07-07       Impact factor: 3.464

Review 2.  Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.

Authors:  Lola Llobat; Olivia Gourbault
Journal:  Biomedicines       Date:  2021-04-23

3.  CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis.

Authors:  Bo Zhang; Jian Zhou
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  Simulated microgravity with floating environment promotes migration of non-small cell lung cancers.

Authors:  Chi Bum Ahn; Ji-Hyun Lee; Dae Geun Han; Hyun-Wook Kang; Sung-Ho Lee; Jae-Ik Lee; Kuk Hui Son; Jin Woo Lee
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

5.  LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.

Authors:  Dong Fu; Chunwen Lu; Xingzhou Qu; Peng Li; Kai Chen; Liancheng Shan; Xiaodong Zhu
Journal:  Aging (Albany NY)       Date:  2019-10-10       Impact factor: 5.682

6.  LINC01278 is Highly Expressed in Osteosarcoma and Participates in the Development of Tumors by Mediating the miR-134-5p/KRAS Axis.

Authors:  Guo-Feng Zhang; Bai-Sui Zhou; Xiao-Chun An; Feng-Min An; Shan-Hui Li
Journal:  Onco Targets Ther       Date:  2021-01-26       Impact factor: 4.147

Review 7.  Matrix Metalloproteinase 3: A Promoting and Destabilizing Factor in the Pathogenesis of Disease and Cell Differentiation.

Authors:  Jiangtao Wan; Guowei Zhang; Xin Li; Xianshuai Qiu; Jun Ouyang; Jingxing Dai; Shaoxiong Min
Journal:  Front Physiol       Date:  2021-07-02       Impact factor: 4.566

8.  MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway.

Authors:  Wei-Wei Wang; Zhi-Hua Zhao; Li Wang; Pan Li; Kui-Sheng Chen; Jian-Ying Zhang; Wen-Cai Li; Guo-Zhong Jiang; Xiang-Nan Li
Journal:  EBioMedicine       Date:  2019-08-02       Impact factor: 8.143

Review 9.  Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Authors:  Timothy M Fan; Ryan D Roberts; Michael M Lizardo
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

10.  Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade.

Authors:  Qiang Zhang; Jiaqi Wu; Xiangfeng Zhang; Le Cao; Yongping Wu; Xudong Miao
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.